40.74

0.84% -0.43

Exelixis Inc (EXEL)

Überblick Nachrichten Preisverlauf Optionskette Financials Warum fällt EXEL? Forum Prognose

Schlusskurs vom Vortag:

$41.17

Offen:

$41.665

24-Stunden-Volumen:

371.83K

Relative Volume:

0.14

Marktkapitalisierung:

$10.59B

Einnahmen:

$2.29B

Nettoeinkommen (Verlust:

$677.90M

KGV:

17.15

EPS:

2.3753

Netto-Cashflow:

$779.77M

1W Leistung:

-1.73%

1M Leistung:

-7.05%

6M Leistung:

+4.28%

1J Leistung:

+10.94%

1-Tages-Spanne:

$40.72

$41.74

1-Wochen-Bereich:

$40.52

$42.66

52-Wochen-Spanne:

$32.38

$49.62

Exelixis Inc Stock (EXEL) Company Profile

Firmenname

Exelixis Inc

Sektor

Healthcare (1118)

Branche

Biotechnology (616)

Telefon

(650) 837-7000

Adresse

1851 HARBOR BAY PARKWAY, ALAMEDA, CA

Mitarbeiter

1,077

Twitter

@exelixisinc

Nächster Verdiensttermin

2025-07-28

Neueste SEC-Einreichungen

EXEL's Discussions on Twitter

Compare EXEL vs VRTX, REGN, ARGX, ALNY, ONC

Aktien	Preis	Marktkapitalisierung	Umsatz	Nettogewinn	Free Cashflow	ENV
EXEL Exelixis Inc	40.76	10.69B	2.29B	677.90M	779.77M	2.3753
VRTX Vertex Pharmaceuticals Inc	471.00	121.46B	12.07B	3.95B	3.19B	15.33
REGN Regeneron Pharmaceuticals Inc	745.24	78.93B	14.34B	4.50B	3.77B	41.56
ARGX Argen X Se Adr	701.00	43.87B	4.16B	1.29B	734.26M	19.59
ALNY Alnylam Pharmaceuticals Inc	313.99	42.07B	3.71B	313.75M	465.38M	2.2571
ONC Beone Medicines Ltd Adr	284.45	31.65B	5.36B	287.73M	924.18M	2.5229

Exelixis Inc Stock (EXEL) Upgrades & Downgrades

Datum	Aktion	Analytiker	Ratingänderung
2026-01-08	Herabstufung	Morgan Stanley	Overweight → Equal-Weight
2026-01-05	Herabstufung	BofA Securities	Neutral → Underperform
2025-11-18	Eingeleitet	Wolfe Research	Peer Perform
2025-11-03	Herabstufung	Guggenheim	Buy → Neutral
2025-10-21	Hochstufung	Leerink Partners	Market Perform → Outperform
2025-09-19	Fortgesetzt	Barclays	Equal Weight
2025-09-17	Fortgesetzt	Barclays	Equal Weight
2025-09-17	Eingeleitet	Goldman	Buy
2025-07-08	Herabstufung	RBC Capital Mkts	Outperform → Sector Perform
2025-06-24	Hochstufung	Stephens	Equal-Weight → Overweight
2025-02-24	Herabstufung	Wells Fargo	Overweight → Equal Weight
2025-01-27	Hochstufung	Morgan Stanley	Equal-Weight → Overweight
2025-01-24	Herabstufung	Oppenheimer	Outperform → Perform
2024-12-20	Herabstufung	BMO Capital Markets	Outperform → Market Perform
2024-12-17	Herabstufung	BofA Securities	Buy → Neutral
2024-10-16	Bestätigt	RBC Capital Mkts	Outperform
2024-09-19	Eingeleitet	UBS	Neutral
2024-04-11	Herabstufung	Barclays	Overweight → Equal Weight
2023-12-19	Eingeleitet	BTIG Research	Buy
2023-12-15	Eingeleitet	Citigroup	Buy
2023-09-26	Eingeleitet	H.C. Wainwright	Buy
2023-08-22	Bestätigt	Oppenheimer	Outperform
2023-08-08	Eingeleitet	SVB Securities	Market Perform
2023-07-11	Fortgesetzt	Morgan Stanley	Equal-Weight
2023-05-10	Fortgesetzt	Piper Sandler	Overweight
2023-03-09	Eingeleitet	Wells Fargo	Overweight
2023-01-26	Eingeleitet	Credit Suisse	Outperform
2022-10-18	Eingeleitet	JMP Securities	Mkt Outperform
2022-06-24	Eingeleitet	BMO Capital Markets	Outperform
2021-11-19	Eingeleitet	Piper Sandler	Overweight
2021-11-03	Fortgesetzt	Jefferies	Buy
2021-10-07	Eingeleitet	Jefferies	Buy
2021-08-06	Bestätigt	H.C. Wainwright	Buy
2021-06-15	Eingeleitet	H.C. Wainwright	Buy
2021-05-18	Fortgesetzt	Goldman	Sell
2021-03-31	Eingeleitet	Credit Suisse	Outperform
2021-03-12	Eingeleitet	Wolfe Research	Outperform
2020-03-04	Eingeleitet	Barclays	Overweight
2020-01-13	Eingeleitet	SunTrust	Buy
2019-11-13	Eingeleitet	BofA/Merrill	Buy
2019-03-18	Hochstufung	Morgan Stanley	Underweight → Equal-Weight
2018-09-17	Eingeleitet	Goldman	Neutral
2018-09-10	Eingeleitet	Morgan Stanley	Underweight
2018-05-11	Bestätigt	Needham	Buy
2017-10-17	Bestätigt	Needham	Buy
2017-10-17	Bestätigt	RBC Capital Mkts	Outperform
2017-10-16	Bestätigt	SunTrust	Buy
2017-09-22	Herabstufung	Leerink Partners	Outperform → Mkt Perform
2017-09-15	Eingeleitet	RBC Capital Mkts	Outperform
2017-09-12	Bestätigt	Needham	Buy
2017-07-14	Eingeleitet	SunTrust	Buy
2017-03-31	Eingeleitet	Needham	Buy
2017-03-16	Eingeleitet	Oppenheimer	Perform
2017-02-28	Herabstufung	Stifel	Buy → Hold
2016-11-03	Eingeleitet	Deutsche Bank	Buy
2016-10-10	Hochstufung	Piper Jaffray	Neutral → Overweight
2016-09-15	Bestätigt	Stifel	Buy

Alle ansehen

Exelixis Inc Aktie (EXEL) Neueste Nachrichten

06:30 AM

Assessing Exelixis (EXEL) Valuation After Analysts Lift 2026 Earnings Forecasts - simplywall.st

06:30 AM

Mar 12, 2026

Exelixis (EXEL) Down 2.8% Since Last Earnings Report: Can It Rebound? - Yahoo Finance

Mar 12, 2026

Here’s What Makes Exelixis (EXEL) a Top Growth Stock - Bitget

Mar 12, 2026

Here's Why Exelixis (EXEL) is a Strong Growth Stock - Yahoo Finance

Mar 12, 2026

Mar 11, 2026

Exelixis at Barclays Healthcare: Strategic Growth and Pipeline Insights By Investing.com - Investing.com Canada

Mar 11, 2026

EXEL: Zanzalintinib and CABOMETYX anchor growth in GI/GU oncology, with robust pipeline momentum - TradingView

Mar 11, 2026

EXEL: Zanza and new indications drive growth, targeting $2.4B revenue and leadership in key oncology markets - TradingView

Mar 11, 2026

First Trust Advisors LP Has $59.35 Million Holdings in Exelixis, Inc. $EXEL - MarketBeat

Mar 11, 2026

Barclays PLC Boosts Stock Holdings in Exelixis, Inc. $EXEL - MarketBeat

Mar 11, 2026

Mar 10, 2026

Exelixis at Leerink Global Healthcare Conference: Strategic Insights in RCC and CRC - Investing.com Canada

Mar 10, 2026

Exelixis Q4 2025 slides: Strong earnings growth amid oncology franchise expansion - Investing.com Nigeria

Mar 10, 2026

Dimensional Fund Advisors LP Grows Holdings in Exelixis, Inc. $EXEL - MarketBeat

Mar 10, 2026

Victory Capital Management Inc. Acquires 187,034 Shares of Exelixis, Inc. $EXEL - MarketBeat

Mar 10, 2026

Mar 09, 2026

What is Zacks Research's Estimate for Exelixis Q3 Earnings? - MarketBeat

Mar 09, 2026

Mar 08, 2026

Crossmark Global Holdings Inc. Boosts Stock Position in Exelixis, Inc. $EXEL - MarketBeat

Mar 08, 2026

Mar 07, 2026

Exelixis, Inc. Experiences Revision in Stock Evaluation Amid Market Dynamics - Markets Mojo

Mar 07, 2026

Gainers Report: Will Exelixis Inc benefit from rising consumer demandWeekly Trend Summary & Smart Investment Allocation Tips - baoquankhu1.vn

Mar 06, 2026

Exelixis, Inc. (NASDAQ:EXEL) Given Average Recommendation of "Hold" by Analysts - MarketBeat

Mar 06, 2026

American Century Companies Inc. Raises Position in Exelixis, Inc. $EXEL - MarketBeat

Mar 06, 2026

Mar 05, 2026

Elo Mutual Pension Insurance Co Buys 30,279 Shares of Exelixis, Inc. $EXEL - MarketBeat

Mar 05, 2026

Mar 04, 2026

A Look At Exelixis (EXEL) Valuation As Analyst Optimism Builds Around Its Oncology Pipeline - simplywall.st

Mar 04, 2026

Mar 03, 2026

EXEL: Zanzalintinib advances toward launch as pivotal trials and franchise expansion drive future growth - TradingView

Mar 03, 2026

Forecasting The Future: 11 Analyst Projections For Exelixis - Sahm

Mar 03, 2026

Is Improving Analyst Sentiment Reframing Exelixis (EXEL) Oncology Pipeline As A Core Valuation Anchor? - simplywall.st

Mar 03, 2026

Mar 02, 2026

Exelixis (EXEL) EVP Haley granted 40,459 RSUs vesting from 2027 - Stock Titan

Mar 02, 2026

Exelixis (NASDAQ: EXEL) CEO granted RSUs, gifts 100K shares - Stock Titan

Mar 02, 2026

Exelixis stock falls after rival Merck trial shows better results By Investing.com - Investing.com India

Mar 02, 2026

Exelixis stock falls after rival Merck trial shows better results - Investing.com Australia

Mar 02, 2026

RBC Capital Lowers Exelixis (EXEL) Price Target to $43 | EXEL St - GuruFocus

Mar 02, 2026

Royal Bank Of Canada Issues Pessimistic Forecast for Exelixis (NASDAQ:EXEL) Stock Price - MarketBeat

Mar 02, 2026

Why Exelixis (EXEL) Stands Out as a Leading Value Investment for Long-Term Growth - Bitget

Mar 02, 2026

Exelixis (NASDAQ:EXEL) Shares Down 9.4% After Analyst Downgrade - MarketBeat

Mar 02, 2026

Why Exelixis (EXEL) is a Top Value Stock for the Long-Term - Yahoo Finance

Mar 02, 2026

RBC Lowers Price Target on Exelixis to $43 From $46, Keeps Sector Perform Rating - marketscreener.com

Mar 02, 2026